168 related articles for article (PubMed ID: 30161251)
1. Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits.
El-Say KM; Hosny KM
PLoS One; 2018; 13(8):e0203405. PubMed ID: 30161251
[TBL] [Abstract][Full Text] [Related]
2. Formulation, Characterization, and Evaluation of Eudragit-Coated Saxagliptin Nanoparticles Using 3 Factorial Design Modules.
Alhamhoom Y; Ravi G; Osmani RAM; Hani U; Prakash GM
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364338
[No Abstract] [Full Text] [Related]
3. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery.
Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A
AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study.
Sharma M; Sharma R; Jain DK; Saraf A
Int J Biol Macromol; 2019 Aug; 135():246-260. PubMed ID: 31128197
[TBL] [Abstract][Full Text] [Related]
5. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
[TBL] [Abstract][Full Text] [Related]
6. Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction.
Hosny KM; Aljaeid BM
Expert Opin Drug Deliv; 2014 Jul; 11(7):1015-22. PubMed ID: 24746063
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization,
Patel MH; Mundada VP; Sawant KK
Drug Dev Ind Pharm; 2019 Aug; 45(8):1242-1257. PubMed ID: 30880488
[No Abstract] [Full Text] [Related]
8. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
9. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization.
Khames A; Khaleel MA; El-Badawy MF; El-Nezhawy AOH
Int J Nanomedicine; 2019; 14():2515-2531. PubMed ID: 31040672
[TBL] [Abstract][Full Text] [Related]
10. Optimized Nanoparticles for Enhanced Oral Bioavailability of a Poorly Soluble Drug: Solid Lipid Nanoparticles Versus Nanostructured Lipid Carriers.
Darwish MKM; El-Enin ASMA; Mohammed KHA
Pharm Nanotechnol; 2022; 10(1):69-87. PubMed ID: 35142275
[TBL] [Abstract][Full Text] [Related]
11. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
[TBL] [Abstract][Full Text] [Related]
12. Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration.
Shah MK; Madan P; Lin S
Pharm Dev Technol; 2014 Jun; 19(4):475-85. PubMed ID: 23697916
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
14. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition.
Shah P; Chavda K; Vyas B; Patel S
Drug Deliv Transl Res; 2021 Jun; 11(3):1166-1185. PubMed ID: 32804301
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
17. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, and in vivo study of rhein solid lipid nanoparticles for oral delivery.
Feng H; Zhu Y; Fu Z; Li D
Chem Biol Drug Des; 2017 Nov; 90(5):867-872. PubMed ID: 28432812
[TBL] [Abstract][Full Text] [Related]
19. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
20. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
